Harbin Clinic Clinical Rsrch Rome, GA - 30165

Harbin Clinic Clinical Rsrch is categorized under Clinics in Rome, GA .

Harbin Clinic Clinical Rsrch was established in 0, and today employs 1 to 4, earning $100.000.000 to $499.999.999 per year. This is a Clinics business, which does work in the B2C market, and is classified as a Clinics, under code number 6214930 by the NAICS.

If you are seeking more information, feel free to contact Ken Davis, Chief Executive Officer at the company’s single location by writing to 1825 Martha Berry Boulevard Nw, Rome, Georgia GA 30165 or by phoning (706) 295-5331. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Harbin Clinic Clinical Rsrch
Contact Person: Ken Davis, Chief Executive Officer
Address: 1825 Martha Berry Boulevard Nw, Rome, Georgia 30165
Phone Number: (706) 295-5331
Website Address: harbinclinic.com
Annual Revenue (USD): $100.000.000 to $499.999.999
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Clinics
SIC Code: 8011
NAICS Code: 6214930
Share This Business:

Harbin Clinic Clinical Rsrch was started in 0 to provide professional Clinics under the SIC code 8011 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000.000 to $499.999.999 per annum.

Feel free to contact Ken Davis, Chief Executive Officer for inquiries that concern Harbin Clinic Clinical Rsrch by calling the company number (706) 295-5331, as your correspondence is most welcome. Additionally, the physical location of the single location of Harbin Clinic Clinical Rsrch can be found at the coordinates 34.277835,-85.182042 as well as the street address 1825 Martha Berry Boulevard Nw in Rome, Georgia 30165.

For its online presence, you may visit Harbin Clinic Clinical Rsrch’s website at harbinclinic.com and engage with its social media outlets through on Twitter and on Facebook.